Concepedia

Author

Larissa Wenning

Merck & Co., Inc., Rahway, NJ, USA (United States)ORCID

Also Known As

L A Wenning, L WENNING, L. A. Wenning, L. Wenning, L.A. Wenning, Larissa A Wenning, Larissa A. Wenning, Larissa Wenning, Larissa A. Wenning, Leslie Wenning

87

Publications

3.9K

Citations

30

H-Index

98

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)United States Military AcademyCovance (United States)Siriraj HospitalState University of New York
LW

About

Larissa Wenning is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, pharmacology, and hiv.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

23

31

1.6K

2

Health Sciences

5

5

630

3

Engineering

1

1

30

4

Natural Sciences

1

1

25

5

Public Health

1

1

25

Larissa Wenning

×

51

Publications

3.6K

Citations

28

H-Index

YearCitations

Rapid and Durable Antiretroviral Effect of the HIV-1 Integrase Inhibitor Raltegravir as Part of Combination Therapy in Treatment-Naive Patients With HIV-1 Infection

Martin Markowitz, Bach‐Yen Nguyen, Eduardo Gotuzzo,

JAIDS Journal of Acquired Immune Deficiency Syndromes

2007

407

Antiretroviral Activity, Pharmacokinetics, and Tolerability of MK-0518, a Novel Inhibitor of HIV-1 Integrase, Dosed As Monotherapy for 10 Days in Treatment-Naive HIV-1-Infected Individuals

Martin Markowitz, Javier O Morales-Ramirez, Bach‐Yen Nguyen,

JAIDS Journal of Acquired Immune Deficiency Syndromes

2006

363

Modeling pO2 Distributions in the Bone Marrow Hematopoietic Compartment. II. Modified Kroghian Models

Dominic C. Chow, Larissa Wenning, William M. Miller,

Biophysical Journal

2001

300

Metabolism and Disposition in Humans of Raltegravir (MK-0518), an Anti-AIDS Drug Targeting the Human Immunodeficiency Virus 1 Integrase Enzyme

Kelem Kassahun, Ian McIntosh, Donghui Cui,

Drug Metabolism and Disposition

2007

274

Modeling pO2 Distributions in the Bone Marrow Hematopoietic Compartment. I. Krogh's Model

Dominic C. Chow, Larissa Wenning, William M. Miller,

Biophysical Journal

2001

239

Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial

Joseph J. Eron, Jürgen K. Rockstroh, Jacques Reynes,

The Lancet Infectious Diseases

2011

190

Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial

Mark Sulkowski, Stanislas Pol, Josep Mallolas,

The Lancet Infectious Diseases

2013

180

Effect of Rifampin, a Potent Inducer of Drug-Metabolizing Enzymes, on the Pharmacokinetics of Raltegravir

Larissa Wenning, William D. Hanley, Diana M. Brainard,

Antimicrobial Agents and Chemotherapy

2009

160

Pharmacokinetics and Pharmacodynamics of Once-Daily versus Twice-Daily Raltegravir in Treatment-Naïve HIV-Infected Patients

Matthew L. Rizk, Yaming Hang, Wen‐Lin Luo,

Antimicrobial Agents and Chemotherapy

2012

92

Atazanavir Modestly Increases Plasma Levels of Raltegravir in Healthy Subjects

Marian Iwamoto, Larissa Wenning, Goutam C. Mistry,

Clinical Infectious Diseases

2008

87

Page 1